HOME >> MEDICINE >> NEWS
BIDMC investigator receives Novartis Award in Diabetes

metabolic abnormalities found in these individuals, who have experienced a generalized loss of adipose tissue. His other research interests extend to other molecules important in the regulation of energy homeostasis including resistin, ghrelin, and GLP-1.

A graduate of Athens (Greece) University Medical School with both M.D. and D.Sc. degrees, Mantzoros holds an M.Sc. degree in Public Health from the Harvard School of Public Health and an M.M.Sc. degree in Clinical Investigation from Harvard Medical School. After completing clinical and research fellowships in Endocrinology, Diabetes and Metabolism through the Longwood Medical Area/Harvard Medical School training program, Mantzoros joined the staff of BIDMC. He is an Overseer of Clinical Research in Endocrinology, Diabetes and Metabolism at BIDMC and Joslin Diabetes Center.


'"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
17-Jun-2005


Page: 1 2

Related medicine news :

1. BIDMCs Terry Strom, M.D., honored by American Society of Nephrology
2. BIDMCs Shapiro Simulation and Skills Center receives American College of Surgeons accreditation
3. BIDMCs Harold Dvorak, MD, honored by National Foundation for Cancer Research
4. BIDMCs Harvey Goldman, MD, receives distinguished pathologist award
5. BIDMC investigators receive award to study pathways responsible for obesity, type 2 diabetes
6. Damon Runyon renews its $2.25 million investment to support young clinical cancer investigators
7. The Burroughs Wellcome Fund awards $8 million to infectious disease investigators
8. Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G
9. Telebriefing: NIH announces program for new scientific investigators
10. MUHC investigators search for the root of sexual pain in women
11. Indiana University Imaging Center receives $6M grant for kidney research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: BIDMC investigator receives Novartis Award Diabetes

(Date:5/25/2013)... According to a new market report,"Global Homeland ... MarketsandMarkets is expected to reach $544.02 Billion by ... and studies the major market drivers, restraints, and ... of the World. , Browse:, , ... 87 Figures , 175 Pages and ...
(Date:5/25/2013)... 2013 Dr. Farooq Ashraf, founder of ... Dubai, has announced his practice’s adoption of The iFS ... FDA-cleared femtosecond laser proven with more than 10 years ... of LASIK. , “We are happy to announce that ... at our Dubai LASIK practice,” Ashraf said Thursday. “We ...
(Date:5/25/2013)... 25, 2013 Acuity Games ’ innovative ... version of Word Hunt is available today, expanding ... Edge Match, Flash 2, Sudoku and Matchematics will roll out ... gameplay and revolutionary lifetime brain fitness measurement have been re-optimized ... “100 years of brain fitness measurement in your pocket. ...
(Date:5/25/2013)... May 25, 2013 IBISWorld estimates that revenue ... an average annual rate of 28.7% to $1.0 billion in ... 2013. From 2002 and 2008, no new cell therapy products ... relatively modest growth during that period. In the years since, ... new products. This factor contributed to the industry's fast growth ...
(Date:5/25/2013)... For college students, few events can ... are turning to prescription stimulants like Adderall to ... on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm . , ... students who pick up Adderall, “just to help ... a physical and psychological dependency. While initially they ...
Breaking Medicine News(10 mins):Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Acuity Games Apps Come to the iPhone 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
(Date:5/24/2013)... LOVELAND, Colo. , May 24, 2013  Heska Corporation ... veterinary diagnostic and specialty products, announced today that Dr. ... executive officer, and Jason Napolitano , executive ... Second Annual Marcum MicroCap Conference, which is being held May ... at the Grand Hyatt Hotel. The Company,s ...
(Date:5/24/2013)... 24, 2013 In accordance with Rule 17.1 and ... of the United States Exchange Act, Echo Pharma Acquisition Limited ... Elan Corporation (NYSE: ELN). Background On ... an offer for the entire of the issued and to ... "Original Offer").  On 20 May 2013, Royalty ...
(Date:5/24/2013)... England and BOSTON , May ... drug discovery and development company, is pleased to announce that it ... Consultant to augment the Company,s business development capabilities in ... has more than 15 years of experience in business development, licensing ... Perlegen Sciences, Inc., Roche Pharma ( Japan ), Nippon ...
Breaking Medicine Technology:Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
Cached News: